Lundbeck Eyes US, China Investment as Drug Rewards Lag in Europe

Danish pharmaceutical giant Lundbeck will shift its capital investments from Europe to the US and China, citing insufficient innovation incentives in its home region, per CEO statements in March 2026. The strategic pivot reflects Europe’s declining competitiveness in drug development, as regulatory and financial barriers stifle research rewards compared to more supportive markets abroad. Lundbeck’s move underscores a broader industry trend where pharmaceutical firms prioritize regions with stronger intellectual property protections and faster commercialization pathways for new therapies. China and the US offer lucrative growth opportunities, with expanding patient pools, streamlined approval processes, and government-backed incentives for biotech innovation. The decision signals potential long-term economic consequences for Europe’s life sciences sector if policy reforms fail to address lagging investment and innovation support.